Widad Group Bhd mula menjadi tajuk utama berita tempatan sejak Oktober tahun lalu apabila pemegang saham utamanya membuat bidaan bernilai berbilion ringgit untuk mengambil alih PLUS Malaysia Bhd.
KUALA LUMPUR, 15 DECEMBER 2020 – Widad Group Berhad (“Widad Group” or the “Group”), a Bursa Malaysia listed investment holding company which is principally involved in construction activities and integrated facilities management services, announced today that it has signed a Memorandum of Collaboration with Rinani Dynamic Sdn Bhd (“Rinani”).
Rinani is the local representative in Malaysia for VAXART, Inc. (“Vaxart”), an US based entity that is listed on NASDAQ (VXRT) with respect to its ongoing development of an oral based (tablet) Covid-19 vaccine named ‘VXA-Cov2-1’. The appointment of Rinani was made by Majoritas Global Limited (“Majoritas”), a company incorporated in Hong Kong, who in turn is Vaxart’s global representative for Malaysia.
VXA-CoV2-1 is a single-dose COVID-19 tablet vaccine candidate that Vaxart believes can be conveniently distributed and administered without the need for cold-chain storage and distribution.
Under the agreement, Rinani will be collaborating with Widad in the distribution, marketing and selling of the vaccine and other Vaxart products in Malaysia. Widad stated that it is ready to support Rinani Dynamics objective of ensuring that people of Malaysia would be among the first to receive Vaxart’s Vaccine, when it receives the FDA and EUA clearance for commercialization. The vaccine candidate is expected to be entering Phase II of Clinical Trials.
The partners to this collaboration have stated that they will work closely in engaging with the various stakeholders in Malaysia, and this includes a sales and distribution for the vaccine in Malaysia, once the vaccines have received clearance for commercialization. The parties have also expressed their readiness to make a pre-purchase commitment of vaccine doses for Malaysia, which shall be announced at a later date once it materializes.
Widad Group Berhad Managing Director Dato’ Mohd Rizal Mohd Jaafar said: “Widad is determined to support Rinani’s effort in pushing Vaxart’s vaccine in Malaysia, to ensure that the nation would have access to what could be the most practical and sustainable vaccine for a mass vaccination program. Vaxart’s vaccine’s two biggest merit is ONE, that it is design to trigger mucosal immunity, which is the first line of defence against airborne viruses such as Covid-19, providing total protection from infection altogether and TWO being in tablet form, makes it the most ‘user-friendly’ vaccine, creating a hassle free, painless experience, one which I feel the people would greatly appreciate and would be encouraged to take.”
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
takerisk
78 posts
Posted by takerisk > 2020-10-14 18:15 | Report Abuse
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3096244